Clinical Trial Update: Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial comparing HOE901-U300 to Lantus in children and adolescents with Type 1 diabetes mellitus completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• HOE901-U300
• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Type 1 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2019-06-19